Disparities in anti-nucleocapsid and anti-spike SARS-CoV-2 antibody prevalence in NYC — April–October 2021

IF 3.3 3区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Annals of Epidemiology Pub Date : 2025-02-01 DOI:10.1016/j.annepidem.2024.12.008

Anne Schuster , Erik J. Kopping , Jo-Anne Caton , Emily Spear , Steven Fernandez , Randal C. Fowler , Jing Wu , Scott Hughes , Amber Levanon Seligson , L. Hannah Gould

{"title":"Disparities in anti-nucleocapsid and anti-spike SARS-CoV-2 antibody prevalence in NYC — April–October 2021","authors":"Anne Schuster , Erik J. Kopping , Jo-Anne Caton , Emily Spear , Steven Fernandez , Randal C. Fowler , Jing Wu , Scott Hughes , Amber Levanon Seligson , L. Hannah Gould","doi":"10.1016/j.annepidem.2024.12.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Between April-October 2021, the New York City (NYC) Health Department conducted a serosurvey to assess prevalence of SARS-CoV-2 antibodies in NYC adults as part of continued COVID-19 surveillance efforts. Methods: Whole blood specimens were collected from 1035 adult NYC residents recruited from an annual population-based health surveillance survey. Specimens were tested for the presence of anti-SARS-CoV-2 spike protein (anti-spike) and anti-SARS-CoV-2 nucleocapsid protein (anti-nucleocapsid) antibodies. Results: 91.6 % (95 % CI: 87.45–94.50) had anti-spike antibodies and 30.4 % (95 % CI: 24.78–36.7) had anti-nucleocapsid antibodies. Almost all participants with anti-spike antibodies produced antibodies capable of neutralizing SARS-CoV-2. Overall, anti-spike positivity was lowest (85.9 % [95 % CI: 74.01–92.85) in Hispanic and Latino New York City residents. Anti-nucleocapsid seropositivity was lowest in Asian/Pacific Islander New York City residents (14.1%, 95% CI: 8.0-23.5). Continued disparities persist in SARS-CoV-2 seropositivity regarding ethnic and sociodemographic factors. Conclusions: SARS-CoV-2 seropositivity was high in 2021 in NYC, with evidence of continued inequities associated with seroprevalence.</div></div>","PeriodicalId":50767,"journal":{"name":"Annals of Epidemiology","volume":"102 ","pages":"Pages 1-7"},"PeriodicalIF":3.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1047279724002813","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Between April-October 2021, the New York City (NYC) Health Department conducted a serosurvey to assess prevalence of SARS-CoV-2 antibodies in NYC adults as part of continued COVID-19 surveillance efforts. Methods: Whole blood specimens were collected from 1035 adult NYC residents recruited from an annual population-based health surveillance survey. Specimens were tested for the presence of anti-SARS-CoV-2 spike protein (anti-spike) and anti-SARS-CoV-2 nucleocapsid protein (anti-nucleocapsid) antibodies. Results: 91.6 % (95 % CI: 87.45–94.50) had anti-spike antibodies and 30.4 % (95 % CI: 24.78–36.7) had anti-nucleocapsid antibodies. Almost all participants with anti-spike antibodies produced antibodies capable of neutralizing SARS-CoV-2. Overall, anti-spike positivity was lowest (85.9 % [95 % CI: 74.01–92.85) in Hispanic and Latino New York City residents. Anti-nucleocapsid seropositivity was lowest in Asian/Pacific Islander New York City residents (14.1%, 95% CI: 8.0-23.5). Continued disparities persist in SARS-CoV-2 seropositivity regarding ethnic and sociodemographic factors. Conclusions: SARS-CoV-2 seropositivity was high in 2021 in NYC, with evidence of continued inequities associated with seroprevalence.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纽约市抗核衣壳和抗刺突SARS-CoV-2抗体流行率的差异- 2021年4 - 10月

目的：在2021年4月至10月期间，纽约市卫生局进行了一项血清调查，以评估纽约市成年人中SARS-CoV-2抗体的流行情况，作为持续的COVID-19监测工作的一部分。方法：从每年以人口为基础的健康监测调查中招募的1,035名纽约市成年居民中收集全血标本。检测标本是否存在抗sars - cov -2刺突蛋白（抗刺突）和抗sars - cov -2核衣壳蛋白（抗核衣壳）抗体。结果：91.6% （95% CI: 87.45 ~ 94.50）的患者有抗刺突抗体，30.4% （95% CI: 24.78 ~ 36.7）的患者有抗核衣壳抗体。几乎所有具有抗刺突抗体的参与者都产生了能够中和SARS-CoV-2的抗体。总体而言，纽约市西班牙裔和拉丁裔居民的抗刺突阳性最低（85.9% [95% CI: 74.01-92.85]）。相反，抗核衣壳血清阳性在纽约市黑人居民中最高（39.9%,95% CI: 25.5-49.3）。由于种族和社会人口因素，SARS-CoV-2血清阳性仍然存在差异。结论：2021年纽约市SARS-CoV-2血清阳性水平很高，有证据表明与血清流行率相关的不平等现象仍在继续。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Epidemiology 医学-公共卫生、环境卫生与职业卫生

CiteScore

7.40

自引率

1.80%

发文量

207

审稿时长

59 days

期刊介绍： The journal emphasizes the application of epidemiologic methods to issues that affect the distribution and determinants of human illness in diverse contexts. Its primary focus is on chronic and acute conditions of diverse etiologies and of major importance to clinical medicine, public health, and health care delivery.